NKTR-181 (Nektar Therapeutics), a long-lasting opioids analgesic, acts as a selective mu-opioid receptor (MOR) agonist, is aimed to provide potent drug relief without the inherently high levels of euphoria. Phase III trial has been completed and another phase III trial currently under evaluation. NKTR-181 has been granted Fast Track designation by the US FDA and new drug application (NDA) has been filed for this drug by the company. NKTR-181 is the first analgesic opioid molecule to exhibit a reduction in specific CNS-mediated side effects, like euphoria, through the strategic alteration of brain-entry kinetics.
Egalet-002 (Egalet Corporation), is a pure opioid that acts as opioid mu and kappa agonist; opioid delta agonists. The US FDA has granted Fast Track Designation for this drug. Eaglet Corporation has filed the NDA for this drug candidate. Egalet Corporation initially anticipated the NDA submission of Egalet-002 in 2019. Although the company completed phase III studies for Egalet-002 with proven efficacy, it has determined to delay indefinitely the previously-announced anticipated 2019 filing date for the Egalet-002 NDA, unless the availability of a partner to share the cost. The company is actively seeking partners for Egalet-002 as well as other product candidates.
(MPC-06-ID; Mesoblast) MPC-06-ID also known as Rexlemestrocel-L is a Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) product candidate, currently in the late stage of development for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. This drug works as a “Cell Replacement: Proteoglycan & collagen stimulant”.
Xtampa (Xtampza ER/ oxycodone) is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate-to-severe pain and as an extended-release product for chronic moderate-to-severe pain requiring continuous opioid analgesics for an extended period. It is used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx, which provides extended-release drug delivery while safeguarding against common methods of abuse and tampering including crushing, chewing, and heating and injecting. Xtampza ER is its first product that is utilizing the DETERx technology platform.